News

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and RetroSense Therapeutics LLC, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness, today announced that Allergan has acquired substantially all of the assets of RetroSense in an all-cash transaction.

The selection of RetroSense as one MIT Technology Review’s 50 Smartest Companies in 2016 highlights the technological significance of RetroSense’s novel therapy.

Clinical trial to assess the safety and, potentially efficacy, of novel gene therapy application of optogenetics in patients with retinitis pigmentosa

Patient recruitment underway for Phase I/II clinical study RetroSense Therapeutics, a privately­‐held, clinical-stage biopharmaceutical company, today announced that it has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.

LONDON, United Kingdom, April 27, 2015 – Image Analysis Limited, a privately-held digital health software and services provider of medical imaging analysis in clinical trials and daily clinical practice, has completed a $5.2m venture financing with Danish Research Foundation (DRF) and RBV Capital.